

Veloxis Pharmaceuticals A/S
Amerika Plads 37
2100 Copenhagen Ø
Denmark

15 January 2020

Major shareholder notification

With reference to section 38 of the Danish Capital Markets Act, Lundbeckfond Invest A/S, CVR no. 21 85 55 45, ("Lundbeckfond Invest") - a wholly-owned subsidiary of Lundbeckfonden, CVR. no. 11 81 49 13 - hereby notifies Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67, ("Veloxis Pharmaceuticals") that as of 14 January 2020, Lundbeckfond Invest holds 0 shares in Veloxis Pharmaceuticals corresponding to 0.0 % of the share capital and voting rights as a result of acceptance of the conditional voluntary public offer published by Asahi Kasei Pharma Denmark A/S on 25 November 2019.

Prior to acceptance of the conditional voluntary public offer, Lundbeckfond Invest directly held a total number of 708,629,942 shares of nominal value DKK 0.10 corresponding to approx. 40.7 % of Veloxis Pharmaceutical's share capital and voting rights.

Best regards
Lundbeckfond Invest A/S